Drug-induced lupus erythematosus

Summary

Drug-induced lupus erythematosus (MONDO:0016474) is a disease. A subtype of lupus erythematosus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 23

Clinical features

Signs & symptoms

Clinical features (HPO)

23 HPO clinical features (Orphanet curated; top 23 by frequency):

HPO ID	Term	Frequency
HP:0000790	Hematuria	Very frequent (80-99%)
HP:0000967	Petechiae	Very frequent (80-99%)
HP:0001698	Pericardial effusion	Very frequent (80-99%)
HP:0001701	Pericarditis	Very frequent (80-99%)
HP:0001873	Thrombocytopenia	Very frequent (80-99%)
HP:0001903	Anemia	Very frequent (80-99%)
HP:0002094	Dyspnea	Very frequent (80-99%)
HP:0002829	Arthralgia	Very frequent (80-99%)
HP:0003138	Increased blood urea nitrogen	Very frequent (80-99%)
HP:0003236	Elevated circulating creatine kinase concentration	Very frequent (80-99%)
HP:0003326	Myalgia	Very frequent (80-99%)
HP:0003493	Antinuclear antibody positivity	Very frequent (80-99%)
HP:0003565	Elevated erythrocyte sedimentation rate	Very frequent (80-99%)
HP:0005184	Prolonged QTc interval	Very frequent (80-99%)
HP:0005421	Decreased circulating complement C3 concentration	Very frequent (80-99%)
HP:0011227	Elevated circulating C-reactive protein concentration	Very frequent (80-99%)
HP:0025300	Malar rash	Very frequent (80-99%)
HP:0025343	Lupus anticoagulant	Very frequent (80-99%)
HP:0030057	Autoimmune antibody positivity	Very frequent (80-99%)
HP:0045042	Decreased circulating complement C4 concentration	Very frequent (80-99%)
HP:0001945	Fever	Frequent (30-79%)
HP:0045073	Serositis	Frequent (30-79%)
HP:0025142	Constitutional symptom	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	drug-induced lupus erythematosus
Mondo ID	MONDO:0016474
Orphanet	231111
DOID	DOID:0040093
ICD-11	1239818910
NCIT	C114354
SNOMED CT	80258006
UMLS	C0263591
MedGen	537988
GARD	0020599
MedDRA	10013706
Is cancer (heuristic)	no

Also known as: DIL · DILE · drug induced lupus · drug induced lupus erythematosus · drug-induced lupus

Disease family

This is a subtype of lupus erythematosus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › lupus erythematosus › drug-induced lupus erythematosus

Related subtypes (2): cutaneous lupus erythematosus, systemic lupus erythematosus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.